SLAMF7 and neoplasm: Since recurrences are usually associated with down-regulation of tumor antigen after targeted therapies [11] or incomplete elimination of residual tumor cells, selection of a target antigen that is not down-regulated (such as CS1 and CD38) is an attractive strategy.